Results 211 to 220 of about 1,994,731 (278)
The efficacy and predictive factors of first-line immune checkpoint inhibitors for advanced non-small cell lung cancer with driver or non-driver gene alterations: a retrospective cohort study. [PDF]
J Thorac DisHe Q +8 more
europepmc +1 more source
Crohn's lymphoid aggregates with endothelial clusters colocalise with submucosal fibrosis in fibrostenosing Crohn's disease. [PDF]
J PatholGlinka M +17 more
europepmc +1 more source
Estrogens and the osteoprotegerin/RANK-ligand system
, 2018 Hofbauer, L. C., Viereck, Volker
openaire +1 more source
A simple compound prioritization method for drug discovery considering multi-target binding.
Digit DiscovKubincová A, Mobley DL.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Extraskeletal effects of RANK ligand
2020Receptor activator of nuclear factor-κB ligand (RANKL) is a key factor in osteoclastogenesis and bone resorption and has been established as a therapeutic target in skeletal pathologies, including osteoporosis and bone metastases.
Andy Göbel +2 more
openaire +2 more sources
The International Journal of Biochemistry & Cell Biology, 2007
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire +3 more sources
RANK ligand (RANKL), a key mediator of bone resorption in normal and pathological states, is expressed as membrane-bound or soluble forms by tissues as diverse as lymph nodes, spleen, thymus and bone-forming cells. In normal bone turnover and in bone metastasis, RANKL stimulates the formation and activity of bone-removing cells, osteoclasts, by binding
J M, Blair, Y, Zheng, C R, Dunstan
openaire +3 more sources
OPG, RANK and RANK ligand expression in thyroid lesions
Regulatory Peptides, 2008Receptor activator of NF-kappaB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) play essential roles in bone metabolism. RANKL binds to RANK, which is expressed by osteoclasts whereas OPG acts as its decoy receptor blocking the RANK-RANKL interaction.
Marie-Françoise, Heymann +5 more
openaire +3 more sources